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Abstract
Background: Administrative databases provide efficient methods to estimate influenza vaccine effectiveness (IVE) against
severe outcomes in the elderly but are prone to intractable bias. This study returns to one of the linked population
databases by which IVE against hospitalization and death in the elderly was first assessed. We explore IVE across six more
recent influenza seasons, including periods before, during, and after peak activity to identify potential markers for bias.
Methods and Findings: Acute respiratory hospitalization and all-cause mortality were compared between immunized/non-
immunized community-dwelling seniors $65years through administrative databases in Manitoba, Canada between 2000-01
and 2005-06. IVE was compared during pre-season/influenza/post-season periods through logistic regression with
multivariable adjustment (age/sex/income/residence/prior influenza or pneumococcal immunization/medical visits/
comorbidity), stratification based on prior influenza immunization history, and propensity scores. Analysis during pre-
season periods assessed baseline differences between immunized and unimmunized groups. The study population
included ,140,000 seniors, of whom 50–60% were immunized annually. Adjustment for key covariates and use of
propensity scores consistently increased IVE. Estimates were paradoxically higher pre-season and for all-cause mortality vs.
acute respiratory hospitalization. Stratified analysis showed that those twice consecutively and currently immunized were
always at significantly lower hospitalization/mortality risk with odds ratios (OR) of 0.60 [95%CI0.48–0.75] and 0.58 [0.53–0.64]
pre-season and 0.77 [0.69–0.86] and 0.71 [0.66–0.77] during influenza circulation, relative to the consistently unimmunized.
Conversely, those forgoing immunization when twice previously immunized were always at significantly higher
hospitalization/mortality risk with OR of 1.41 [1.14–1.73] and 2.45 [2.21–2.72] pre-season and 1.21 [1.03–1.43] and 1.78
[1.61–1.96] during influenza circulation.
Conclusions: The most pronounced IVE estimates were paradoxically observed pre-season, indicating bias tending to over-
estimate vaccine protection. Change in immunization habit from that of the prior two years may be a marker for this bias in
administrative data sets; however, no analytic technique explored could adjust for its influence. Improved methods to
achieve valid interpretation of protection in the elderly are needed.
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Introduction
Elderly people ($65 years) experience the greatest burden of
severe complications from seasonal influenza, with more than 90%
of influenza-related deaths estimated to occur annually in that age
group [1,2]. The US Advisory Committee on Immunization
Practice first recommended routine influenza immunization for
the elderly in 1964. The recommendation was predicated on the
increased risk of severe influenza complications in the elderly, but
evidence for vaccine benefit was acknowledged at that time to be
based on extrapolation as follows:
‘‘That influenza vaccine prevents mortality from influenza,
particularly among the aged and chronically ill, is based upon
inference. It is presumed that vaccine protection demonstrated in
studies among younger persons is similar among the aged and
chronically ill, the group at particular risk of death should they
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22618acquire the disease. It is further assumed that such protection
against clinical disease serves to protect them also against mortality
associated with epidemic influenza. No studies, however, have yet
been reported which measure the efficacy of the vaccine in
prevention of influenza-associated mortality.’’ [3]
Consequently, the recommendation to immunize elderly people
against influenza became ‘‘grandfathered’’ into practice in North
America, precluding placebo-controlled trials for ethical reasons.
Only three randomized controlled trials (RCTs) have since
assessed the efficacy of split trivalent inactivated influenza vaccine
(TIV) in preventing laboratory-confirmed influenza in the elderly
[4–6]. None was conducted in North America, none assessed
vaccine protection against serious outcomes, most involved
young/low-risk elderly, and all used serologic outcomes, which,
as recently suggested, may overestimate influenza vaccine effec-
tiveness (IVE) [7]. Two trials assessed serologically-confirmed
influenza illness in community-dwelling elderly showing significant
vaccine protection of 58% (95% confidence interval [CI] 26–
77%;Netherlands,1991–92; [4]) and 65% (16–85%;Bangkok,
1998–99; [6]). One assessed protection among nursing home
residents with a non-significant vaccine efficacy of 50% (226–
80%;Russia,1996–97; [5]).
The remaining evidence for the benefit of TIV in the elderly
comes entirely from observational studies [8–31]. Fedson et al
were among the first to report influenza vaccine effectiveness (IVE)
against hospitalization and death in the elderly using the linked
immunization and health outcome administrative databases for
the population of Manitoba, Canada [9]. Fedson et al reported
IVE against hospital admission for pneumonia of 37–39% and
against all-cause mortality of 27–30% during the 1982–83 and
1985–86 seasons. Subsequent observational studies showed
similarly impressive estimates of vaccine protection. In a 2002
meta-analysis, Vu et al [20] summarized IVE against pneumonia
and influenza hospitalizations across nine studies as 33% (95%CI
19–47%) and against all-cause mortality across four studies as 50%
(95%CI 45–56%). In most studies, adjustment for underlying
health conditions further increased estimates of IVE [10,19,
21,23,25,28]—an effect believed to be the result of accounting for
confounding by indication whereby higher-risk patients may be
more likely to receive vaccine [32]. Estimates were interpreted as
reliable because the same high level of vaccine protection was not
measured outside periods of influenza circulation, notably in the
summer [13,16,21,22,24,28,29].
More recently a Cochrane meta-analysis summarized similar
estimates of IVE but questioned the quality and interpretation of
available data [31]. Others have expressed similar skepticism in
particular because substantial increase in TIV coverage among the
elderly from ,15% to .65% over the past four decades has not
been accompanied by the kind of decrease in influenza-related
mortality implied by such vaccine protection [33]. IVE against all-
cause mortality of 50% is counter-intuitive given that the frac-
tion of winter excess mortality attributed to influenza has never
exceeded 10% over those four decades [33,34]. Rather than
under-estimating IVE through confounding by indication, obser-
vational designs may have instead substantially over-estimated
IVE through healthy user (or healthy vaccinee) bias whereby elderly
patients with poorer prognosis may be less likely to receive vaccine
compared to the healthy [34,35].
Jackson et al illustrated this effect in estimates for IVE against
hospitalization and death that were paradoxically higher pre-
season than during the period of peak influenza activity [36]. In
follow-up case-control and cohort analyses, including detailed
chart review, Jackson and others were able to adjust for specific
markers of functional status and frailty and reported marked
attenuation of vaccine benefit [37,38]. Most influenza deaths were
accrued in a small but special subgroup of under-immunized and
incapacitated elderly experiencing acute decline.
The current study returns to the large longitudinal and linked
Manitoba databases among the first used to assess IVE against
serious outcomes in the elderly. We explore IVE across six more
recent influenza seasons, including periods before, during, and
after peak activity to identify potential markers for bias within
administrative data.
Methods
1. Ethics statement
The University of Manitoba Research Ethics Board and Health
Information Privacy Committee (Manitoba Health) approved the
study. Because anonymized administrative data were used in this
study, individual consent was not required, per the Manitoba
Personal Health Information Act and the evaluation of the Re-
search Ethics Board and Health Information Privacy Committee.
2. Study population and setting
A cohort of community-dwelling adults $65years as of
December 31 was assembled by linking data from the Manitoba
Immunization Monitoring System (MIMS) and the Manitoba
Centre for Health Policy data repository for September 1 to
August 31 of each year from 2000–01 to 2005–06. Residents of
personal care facilities were excluded. Adult immunization with
date of administration has been routinely recorded in MIMS since
2000. For this study, individuals were considered immunized if
their record indicated vaccine receipt by the date when 90% of the
cohort had been immunized for a given study year (first or second
week of November in all years). The remaining 10% of immunized
individuals were excluded from the analysis in order to maintain a
consistent immunized cohort throughout the entire influenza
season. Physician visits, hospital claims, and vital statistics data
were linked to vaccine records at the individual level.
3. Time periods
Weekly counts of influenza isolates recorded by Cadham
Provincial Laboratory (Manitoba) defined discrete periods within
study years including fall, pre-influenza, influenza, peak influenza,
spring, and summer periods as shown in Figure 1. Trends in
health outcomes were explored across these periods each year
and in aggregate. For hospitalization, the five-week fall period
beginning the first week of September each year (weeks 36–40)
prior to the start of the annual immunization campaign was
compared to the influenza period. IVE was calculated for this
fall period by assigning study subjects their immunization status
according to their actual immunization patterns during the coming
season. This comparison was only possible for hospitalization since
by definition those who died during the fall period could not be
categorized based on subsequent immunization status. For all-
cause mortality, comparison was thus based upon the pre-
influenza period defined as the interval from the date by which
90% of elderly immunizations had been administered until the
onset of the influenza period. Trends in relation to both the
influenza and the peak periods were similar so only the former are
presented.
4. Outcomes
Outcomes were all-cause mortality and hospitalization with
pneumonia, influenza, or acute respiratory disease listed as the
‘‘most responsible’’ admission diagnosis. International Classifica-
tion of Disease (ICD-9-CM and ICD-10) diagnostic codes defined
Bias in Elderly Influenza Vaccine Effect
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coding took place April 1, 2004 in Manitoba and appropriate
translations were made.
5. Covariates
The following covariates were considered: age (five-year groups
with the eldest group consisting of those $85years), sex, socio-
economic status (SES), urban residency, comorbid conditions,
number of medical visits in the prior year (0–2, 3–9, $10 visits),
number of influenza immunizations in the prior two years (none,
one, or two), and pneumococcal immunization. Publicly available
census data were used to sort approximately 20% of the Manitoba
population into five ordered income classes, and study subjects
were assigned to an income quintile, as a proxy for SES [39].
Urban residency was defined as residence in Winnipeg or
Brandon. The previously validated Elixhauser Comorbidity Index
[40] provided a measure of comorbidity based on the individual’s
hospital claims two years prior to the start date of each study year.
Diagnostic codes from these hospital claims specified 30 different
comorbidities [40]. The two-year sum Elixhauser Index was
categorized as 0, 1–2, 3–5, 6–9, and $10. The number of prior
medical visits was extracted from the physician claims database
from September 1 of the previous year to August 31 of each
study year, excluding the influenza immunization visit. In 2000
Manitoba introduced pneumococcal immunization for adults age
$65years. For any given study year, pneumococcal immunization
was defined if the vaccine was administered between January 1,
2000 and the first day of the influenza period.
6. Statistical analysis
Overall hospitalization and mortality rates were derived for
each period and year as the number of events divided by the
average living population over the period adjusted for the length of
the period to enable comparisons. Where hospitalization and
mortality rates are presented per year, they are also age-
standardized using the 2006 population. Generalized estimating
equations (GEE) computed aggregate rates across years account-
ing for year-to-year variability and adjusting for age. Aggregate
predicted rates and odds ratios stratified by prior influenza
immunization in the preceding two years were also derived by
GEE adjusting for age, prior medical visits, and pneumococcal
immunization.
Univariate and multivariable IVE estimates were calculated for
each study period/year as one minus the odds ratio for a given
outcome in the immunized compared to the non-immunized [41].
For both outcomes, new risk sets were assembled at the start of
each week of IVE analysis, removing individuals who died in the
previous week.
For yearly analyses, a logistic regression model was fit with
adjustment for potential confounders and exploration of interac-
tion terms. For propensity score analysis [42,43], logistic regression
models were fit with various combinations of covariates in order to
calculate the probability of receiving an influenza vaccine. The
model which yielded the highest c-statistic and lowest Akaike
information criterion (AIC) value and which included all relevant
covariates was selected; subjects were then matched 1:1 based on
current immunization status. Longitudinal GEE models were used
Figure 1. Timeline of seasonal periods of analysis, by study year. Note. Definition of periods as follows: Fall=five week period starting with
first week of September; Pre-Influenza=interval from date by which 90% of elderly immunizations had been administered until onset of influenza
period; Influenza=the interval between and including the first and last occurrences of at least two consecutive weeks with two or more influenza
isolates reported; Peak=five week period including week with peak proportion of respiratory specimens positive for influenza +/2 two weeks;
Spring=interval from/including week after the influenza period to May 31; Summer=interval from/including first week of June to last week of
August. * Pre-influenza period not defined in 2003–04 due to early season.
doi:10.1371/journal.pone.0022618.g001
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approaches. We explored various correlation structures, and
results were similar for auto-regressive 1 and exchangeable me-
thods; exchangeable correlation structure was therefore used for
all analyses. Because of an early start to the influenza season
during the 2003–04 year, a pre-influenza period was not available
for comparison of IVE against all-cause mortality that year. For
that reason, the 2003–04 year was excluded from aggregate IVE
analyses for all periods. For hospitalization, the 2003–04 year was
excluded only from the pre-influenza period analysis since the fall
period was the main referent for that outcome.
Results
Population characteristics
Assembled cohorts ranged in size from 139,185 in 2000–01 to
140,735 in 2005–06: 52%, 52%, 53%, 64%, 62%, and 64%
received influenza vaccine each successive year (Table 1). These
proportions are within 5–10% of vaccine coverage estimates from
the Canadian Community Health Survey for 2000–01 (62%),
2003–04 (60%), and 2005–06 (71%) [44].
Vaccine coverage tended to be higher with advancing age, in
those residing in an urban area, and in people who had received
prior influenza or pneumococcal immunizations or who had $10
medical visits in the prior year (Table 1).
The proportion that had received no influenza immunizations
in the prior two years decreased each successive year from 56% in
2000–01 to 29% in 2005–06, while the proportion that had
received two prior influenza immunizations increased each suc-
cessive year from 27% to 55%. Each study year, those who had
been immunized twice in the preceding two years had the highest
current influenza immunization rates, always exceeding 85%;
conversely, those who had received no dose in the preceding two
years consistently had the lowest influenza immunization rates,
never exceeding 30%.
The proportion of patients who had received pneumococcal
vaccine steadily increased over the course of the study period, from
1% in 2000–01 to 31% in 2005–06 among the influenza non-
immunized, and from 10% in 2000–01 to 85% in 2005–06 among
the immunized.
Hospitalization and mortality
Counts and age-standardized rates for hospitalizations and all-
cause mortality are plotted by period and year in Figures 2a and
2b, respectively. Hospitalization rates show a rise during influenza
periods, lower in the periods before and after, for both immunized
and non-immunized cohorts. However, hospitalization rates were
consistently higher each year among the non-immunized com-
pared to the immunized during the fall period, with greater
variability in relative rates during other periods.
Mortality rates were highest in the non-immunized during
the fall period each year and consistently higher in the non-
immunized compared to the immunized across all periods, most
notably in the period before influenza circulation.
Influenza vaccine effectiveness
Crude IVE estimates and the effects of adjustment for influential
covariates, matching by propensity scores, and stratification by
immunization history are shown for each analysis period in
aggregate in Table 2 and for the influenza period of each year
(with illustration of adjustment by individual covariates) in
Table 3. Adjusted and propensity score-matched estimates were
consistently higher than crude estimates.
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22618Figure 2. Hospitalization (pneumonia, influenza, or acute respiratory disease; panel a) and all-cause mortality (panel b) counts and
rates by immunization status and influenza vaccine effectiveness estimates against hospitalization (panel a) and all-cause
mortality (panel b), adjusted for age, prior medical visits, prior influenza vaccination, and prior pneumococcal vaccination, 2000–
01 to 2005–06. Note. Numbers adjacent to rates represent numerator counts of hospitalizations per period and immunization status stratum;
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22618For most years, during the fall period prior to influenza
circulation, the rate of hospitalization in individuals who would
remain unimmunized was much higher than in those who would
become immunized, representing intrinsic differential between the
ultimately immunized and non-immunized cohorts (Figure 2a).
The calculated IVE was therefore high during that period and
much higher than during the period of influenza transmission.
Adjustment further exacerbated this bias, approximately doubling
IVE estimates in the fall period prior to influenza circulation
(Table 2). In stratified analyses, those who had received influenza
vaccine in each of the preceding two years typically showed the
highest IVE during the influenza period compared to those who
had received none or one prior immunization (Tables 2,3).
IVE estimates against mortality were consistently higher than
those against hospitalization. For all years, IVE against mortality
was highest in the pre-influenza period (Figure 2b), a pattern that
numbers in ‘Aggregate Years’ section represent median counts per period. There is no pre-period for 2003–04 owing to early start of influenza period.
Hospitalization defined as admission with pneumonia, influenza, or acute respiratory disease listed as most responsible diagnosis. IVE=influenza
vaccine effectiveness. * Aggr.=data aggregated across all 6 seasons 2000–01 to 2005–06 (2003–04 excluded for all-cause mortality).
{ Approximate
influenza A versus B circulation (based on national summaries [45]) and match to vaccine components.
doi:10.1371/journal.pone.0022618.g002
Table 2. Aggregate influenza vaccine effectiveness against hospitalization and all-cause mortality estimated by GEE with
adjustment, propensity score matching, and stratification: 2000–01 to 2005–06.
HOSPITALIZATION
e; IVE (95% CI) ALL-CAUSE MORTALITY
g; IVE (95 % CI)
Covariate Adjustment Fall Pre-influenza
f Influenza Summer Pre-influenza Influenza Summer
Crude 26%
(12, 38)
213%
(230, 2)
29%
(221, 2)
27%
(222, 7)
42%
(35, 48)
13%
(6, 20)
4%
(26, 13)
All covariates
a 54%
(42, 64)
11%
(25, 24)
5%
(27, 16)
1%
(214, 14)
62%
(58, 64)
31%
(27, 36)
19%
(13, 25)
Select covariates
b 52%
(40, 62)
8%
(27, 22)
3%
(29, 14)
21%
(217, 13)
66%
(63, 69)
34%
(28, 39)
20%
(13, 26)
Matched propensity scores
c 46%
(32, 57)
9%
(28, 24)
6%
(27, 18)
7%
(210, 22)
58%
(53, 62)
30%
(23, 36)
17%
(8, 25)
Stratified by number of influenza immunizations in prior 2 years:
0 260%
(2116, 219)
263%
(2115, 224)
250%
(280, 226)
250%
(288, 220)
18%
(2, 32)
213%
(230, 2)
213%
(232, 3)
1 52%
(32, 66)
10%
(216, 30)
5%
(215, 21)
18%
(25. 36)
59%
(52, 65)
38%
(30, 46)
21%
(8, 32)
2 74%
(67, 80)
37%
(21, 49)
36%
(23, 46)
22%
(21, 39)
75%
(72, 79)
50%
(44, 56)
39%
(30, 48)
Stratified by number of influenza immunizations in prior 2 years adjusted for all covariates
a
0 257%
(2114, 215)
248%
(288, 216)
236%
(260, 216)
239%
(267, 216)
33%
(21, 43)
9%
(24, 20)
1%
(212, 13)
1 68%
(54, 77)
35%
(16, 50)
38%
(25, 49)
41%
(24, 53)
56%
(49, 62)
34%
(25, 42)
11%
(23, 23)
2 81%
(75, 85)
41%
(27, 53)
53%
(43, 61)
37%
(19, 51)
73%
(70, 77)
46%
(40, 52)
32%
(22, 40)
Stratified by number of influenza immunizations in prior 2 years and adjusted for select covariates
d
0 233%
(281, 2)
234%
(273, 24)
227%
(251, 27)
231%
(260, 27)
21%
(7, 33)
23%
(216, 9)
27%
(221, 6)
1 57%
(40, 69)
17%
(26, 35)
9%
(29, 24)
24%
(3, 40)
62%
(56, 67)
42%
(35, 48)
25%
(14, 34)
2 74%
(67, 79)
36%
(21, 47)
36%
(24, 46)
21%
(0, 38)
76%
(73, 78)
51%
(45, 56)
40%
(33, 47)
Note. IVE=influenza vaccine effectiveness; CI=confidence interval.
aAll covariates include: age, sex, socio-economic status, urban residency, prior influenza immunization (two year), prior pneumococcal immunization, medical visits prior
year, and Elixhauser index;
bSelect covariates include: age, prior influenza immunization (two year), pneumococcal immunization, medical visits prior year;
cMatched on propensity scores derived based on all covariates: age, sex, socio-economic status, urban residency, prior influenza immunization (two year), prior
pneumococcal immunization, medical visits prior year, and Elixhauser index;
dSelect adjustment includes: age, prior pneumococcal immunization, medical visits prior year;
ePneumonia, influenza, or acute respiratory disease listed as most responsible admission diagnosis;
fPre-influenza period estimates for hospitalization do not include 2003–04;
g2003–04 year excluded from all estimates related to all-cause mortality since the pre-influenza period constitutes the main comparison period for that outcome and
was missing for 2003–04 owing to early influenza period.
doi:10.1371/journal.pone.0022618.t002
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were lower during the influenza period but higher than those for
the summer (Table 2). In stratified analyses, those who had
received influenza vaccine in each of the preceding two years
showed the highest IVE against all-cause mortality and those who
had not previously received any doses derived the lowest IVE
(Tables 2,3).
Hospitalization and mortality by prior immunization
history
Because stratification based on immunization in the previous
two years showed an influence on IVE estimates, we plotted hos-
pitalization and mortality rates and derived odds ratios stratified
by historic and current immunization. These are shown as
aggregate estimates for all study years adjusted for age, prior medi-
cal visits, and prior pneumococcal immunization in Figures 3a/
3b and Table 4.
The elderly who were previously immunized and continued
to receive vaccine experienced the lowest hospitalization and
mortality rates across all analysis periods. The previously unim-
munized who received vaccine had the highest hospitalization
rates during the influenza period. Those forgoing immunization
who had twice previously received vaccine had the second highest
hospitalization rates during the influenza period, but their rates
were already greater compared to other groups during the fall and
pre-influenza period, with steady decline thereafter. Mortality
rates in those forgoing immunization despite prior receipt showed
the same pattern of decline from a fall excess compared to the
immunized in whom mortality was lower and more stable across
all analysis periods, regardless of prior immunization history.
Odds ratios to quantify the risk between immunized and
unimmunized elderly according to prior immunization history are
shown in Table 4, with the consistently non-immunized as
referent. For those previously immunized, forgoing immunization
was associated with a significantly higher likelihood of both hospi-
talization and death that was evident in advance of the influenza
period. Conversely, those who were previously and again immu-
nized were at significantly lower risk at all times. Those choosing to
be newly immunized were at significantly higher risk for hospi-
talization (but not death) before and during the influenza season.
Given the disproportionate contribution of previously versus never
immunized to the total cohort, results suggest an overall tendency to
over-estimate IVE against severe outcomes in the elderly.
Discussion
This study returned to the administrative databases that were
among the first to show substantial reduction in serious influenza
outcomes among immunized elderly. In revisiting the Manitoba
database, we exposed similar evidence for bias that others have
found, with the most pronounced but implausible effects (i.e.,
differences between immunized and non-immunized groups) ob-
served in the elderly prior to influenza circulation or even vaccine
Table 4. Adjusted odds ratios for hospitalization and death by prior and current influenza immunization status.
Adjusted
a odds ratio (95% CI)
Two year prior immunization history;
current immunization Fall Pre-Influenza Influenza Summer
Hospitalizations
b
None; unimmunized Ref Ref Ref Ref
None; immunized 1.34 (1.00, 1.78) 1.38 (1.10, 1.74) 1.29 (1.12, 1.49) 1.35 (1.14, 1.60)
One; unimmunized 1.66 (1.25, 2.20) 1.29 (1.04, 1.61) 1.24 (1.06, 1.47) 1.29 (1.06, 1.57)
One; immunized 0.73 (0.56, 0.94) 1.1 (0.90, 1.29) 1.10 (0.97, 1.25) 0.99 (0.86, 1.15)
Two; unimmunized 2.34 (1.82, 2.99) 1.41 (1.14, 1.73) 1.21 (1.03, 1.43) 1.01 (0.80, 1.27)
Two; immunized 0.60 (0.48, 0.75) 0.89 (0.76, 1.04) 0.77 (0.69, 0.86) 0.78 (0.68, 0.90)
Deaths (All-cause)
None; unimmunized n/a Ref Ref Ref
None; immunized n/a 0.76 (0.65,0.89) 0.94 (0.84, 1.05) 1.07 (0.67, 1.18)
One; unimmunized n/a 1.73 (1.57,1.92) 1.66 (1.51, 1.82) 1.30 (1.17, 1.45)
One; immunized n/a 0.68 (0.60,0.76) 0.89 (0.81, 0.96) 1 (0.92, 1.09)
Two; unimmunized n/a 2.45 (2.21,2.72) 1.78 (1.61, 1.96) 1.35 (1.21, 1.51)
Two; immunized n/a 0.58 (0.53,0.64) 0.71 (0.66, 0.77) 0.79 (0.73, 0.85)
Note. CI=confidence interval. 2003–04 could not contribute to pre-influenza period for hospitalizations and was excluded from all periods for mortality owing to early
start to influenza season that year.
aAdjusted for age, prior pneumococcal immunization, and medical visits prior year.
bPneumonia, influenza, or acute respiratory disease listed as most responsible admission diagnosis.
doi:10.1371/journal.pone.0022618.t004
Figure 3. Aggregated hospitalization (pneumonia, influenza, or acute respiratory disease; panel a) and all-cause mortality (panel b)
rates by prior & current immunization status, by period, 2000–01 to 2005–06. Note. Based on GEE model adjusting for age, prior medical
visits, and prior pneumococcal vaccination, and accounting for year-to-year variation. 2003–04 excluded from pre-influenza period analyses for
hospitalization and from all analysis periods for mortality owing to early start of influenza period. Hospitalization defined as admission with
pneumonia, influenza, or acute respiratory disease listed as most responsible diagnosis.
doi:10.1371/journal.pone.0022618.g003
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relative to the preceding two years may be a readily accessible and
recognizable marker for this bias.
We defined immunization status based on vaccine receipt by the
first two weeks of November for a given year (the period by which
90% of those immunized had received vaccine). Based on that
consistent categorization, we found that the ultimately non-
immunized group had higher hospitalization and mortality rates
than the immunized before the period of influenza circulation.
Given the impossibility of a true vaccine effect during the fall
period prior to vaccine distribution, multiple analytical methods
were evaluated based on the degree by which they could reduce
this obvious positive bias. As in other studies, adjustment by
standard regression and propensity score matching only exacer-
bated bias, substantially increasing IVE estimates against hospi-
talization and death before and during the influenza period.
Simonsen et al have suggested three criteria to identify residual
bias in observational studies of IVE [33]. The first criterion
specifies that a null vaccine effect should be observed during pre-
influenza periods. As already discussed, this was not shown in our
study. Secondly, IVE should be least pronounced during seasons
when vaccine components are poorly-matched to circulating
strains. As shown in Figures 2a/2b, we found no obvious
correlation between vaccine match and IVE estimates. Lastly, IVE
estimates should be most pronounced for more specific outcomes
(e.g., pneumonia and influenza hospitalization) and less so for non-
specific outcomes (e.g., all-cause mortality). In our study, as in
others, the reverse was true.
In combination, this framework signals substantial bias in our
estimates of IVE derived using classical methods and a well-
established administrative database similar to that typically used by
others reporting substantial vaccine protection. Further stratifica-
tion based on prior influenza immunization revealed at least one
obvious indicator of this bias: rates of hospitalization and death
varied with change in immunization habit relative to the preceding
two years. We showed high rates of hospitalization and death
among those forgoing immunization after having twice consecu-
tively received vaccine—an excess that was greatest even before the
influenza period began—highlighting a nuanced form of healthy
user bias. These individuals may represent the ‘‘healthy user
recently turned unhealthy’’, whose acute failure to receive vaccine is
a marker for imminent decline, thereby contributing to hospital-
ization and death counts in the unimmunized and spuriously
inflating estimates of vaccine protection. Baxter et al have also
recently shown that forgoing immunization predicts death in those
who had received vaccine in the previous five years but predicts
survival in patients who had never before received vaccine [46]. We
were able to show these same effects based on change from just two
years of influenza immunization habit, suggesting that alteration in
vaccine behavior is a robust predictor of death, albeit one which
could not, through multivariable analysis, correct the bias described
in this paper. In the opposite direction, seeking vaccine after
forgoing for several years may reflect a change in health/risk status
resulting in disproportionate contribution to hospitalization within
the immunized group—a classic form of confounding by indication
spuriously lowering IVE estimates. These forms of bias influence
IVE estimates in opposite directions and may differentially affect
hospitalization and death as serious outcome indicators, adding to
the complexity of analysis based on administrative data sets.
Because of the numerous limitations outlined in this paper, we
resisted citing specific IVE estimates in the discussion of our
findings. Overall, compared to estimates reported by Fedson et al
two decades ago in the same population and with similar methods,
our aggregate estimates for vaccine protection during the influenza
period are slightly higher against all-cause mortality but lower
against hospitalization [9]. We have presented analyses using a
specific hospitalization outcome (pneumonia, influenza, or acute
respiratory disease listed only as most responsible admission
diagnosis) which may not have captured all hospitalizations
attributable to influenza; in preliminary analyses, however, less
specific hospitalization outcomes were also explored (e.g., all-cause
hospitalization), and trends in IVE across periods and methods
were similar to those using the more specific definition. In this
study, we applied the unconventional approach of assigning
immunization status during the fall periods—before the campaign
started—based on a future exposure, with the intent of illustrating
baseline differences between those eventually immunized and
those never immunized in a given season. This approach would
have classified those who died between the fall analysis period and
the availability of vaccine as unimmunized. Although these
individuals did not have the opportunity to receive vaccine in
the subsequent season, any effect of such misclassification on rates
and IVE estimates would be small: of the 408 persons who were
classified as unimmunized and hospitalized during the fall across
the six study seasons, only 12 (3%) died before the start of the pre-
influenza period.
While administrative data sets are recognized as efficient
methods to estimate IVE, the validity of estimates derived in
that way appears highly questionable. Our study illustrates the
profound non-comparability of immunized and non-immunized
individuals which is not corrected, but rather is exacerbated, by
adjustment for standard confounders. Rather than continuing to
assert potentially misleading evidence for protection, we see a
few possible directions for research enhancement. More detailed
exploration of covariates associated with acute decline is clearly
needed. One example, which we were unable to explore in this
study, may be a measure of suddenly stopping long-term medi-
cation for a chronic condition. Instrumental variables as a proxy
for frailty could also be used [47], however, a reliable proxy not
associated with the outcome has been challenging to identify in
studies of IVE [48]. Case-control or nested case-control studies
such as those conducted by Jackson et al have been successful in
addressing functional status and frailty but such studies are labor-
intensive and less amenable to annual repeat [36,37]. Other
methods have also been proposed [46,49–51], but as long as
original RCT evidence for vaccine protection in the elderly
remains scant, it will be impossible to compare findings from
observational studies against a reliable gold standard or to
interpret true vaccine benefit. It may therefore be time to reopen
the discussion for a properly designed RCT, with appropriate
antiviral treatment, data monitoring, oversight, and stopping rules.
Given that placebo-controlled trials may be ethically controversial
in the elderly, randomization to standard versus enhanced (e.g.,
adjuvanted) formulations may be more acceptable.
Until then, our findings add to the growing uncertainty about
whether current influenza vaccines provide needed protection to
the elderly. Insomuch as the elderly suffer the most severe con-
sequences of influenza infection, resolving whether current vaccine
options offer benefit and otherwise advocating for improved ap-
proaches should be priorities for the influenza immunization
program.
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